Publication
TGF beta-mediated MMP13 secretion drives myoepithelial cell dependent breast cancer progression
Publications associées (32)
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
Michele De Palma, Alan Nicolas Thierry Guichard, Mario Leonardo Squadrito, Chiara Cianciaruso, Esra Güç, Ioanna Keklikoglou, Antonino Cassarà
Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...
2019Progestins used for hormonal contraception in Switzerland: study of their effects on the breast epithelium
Breast cancer is the most commonly diagnosed cancer and the most common cause of cancer death among women. Hormones have been shown to have a key role in breast development and carcinogenesis. Repeated activation of progesterone receptor (PR) signaling as ...
EPFL2018Improvement of breast cancer diagnosis through microfluidics
In breast cancer, 15-20% of cases are reported with overexpression of human epidermal growth factor receptor 2 (HER2) that causes rapid cancer progression and poor prognosis. Fortunately, HER2-targeted therapy using specific antibodies such as Trastuzumab ...
EPFL2018Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions
Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Laura Battista, Maryse Fiche, Valentina Scabia, Patrik Aouad, Valérian Charles Robert Dormoy
Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to establish as patient-derived xenografts (PDXs). We and others recently demonstrated that the microenvironment is critical for ER-positive tumor cells; when ...
2018A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response
Cathrin Brisken, Georgios Sflomos, Ayyakkannu Ayyanan, Laura Battista, Maryse Fiche, Valentina Scabia, Valérian Charles Robert Dormoy
Seventy-five percent of breast cancers are estrogen receptor α positive (ER(+)). Research on these tumors is hampered by lack of adequate in vivo models; cell line xenografts require non-physiological hormone supplements, and patient-derived xenografts (PD ...
Elsevier2016TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer
George Coukos, Nicolas Jean Philippe Guex, Luc Henry, Ioannis Xenarios, Hans-Anton Lehr, Nathalie Rufer, Emanuela Marina Iancu
In experimental mouse models of cancer, increasingly compelling evidence point toward a contribution of tumor associated macrophages (TAM) to tumor lymphangiogenesis. Corresponding experimental observations in human cancer remain scarce although lymphatic ...
Taylor & Francis Inc2016Radiologic evaluation of lumps in the male breast
BackgroundGynecomastia has a typical appearance on mammography, and occurs frequently in men. However, imaging is often performed on men with breast lumps to exclude breast cancer, which only comprises 1% of male breast masses.PurposeTo assess whether ultr ...
2016Stratification and therapeutic potential of PML in metastatic breast cancer
Evaristo Jose Planet Letschert
Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, the molecular basis of metastatic breast cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel tar ...
Nature Publishing Group2016SiNW-based Biosensors for Profiling Biomarkers in Breast Tumor Tissues
Breast cancer is the most common life-threatening malignancy in women of most developed countries today, with approximately 200,000 new cases diagnosed every year. About 30% of these cases progress to metastatic disease and death. Considering that one-thir ...
EPFL2016Perivascular M2 macrophages stimulate tumor relapse after chemotherapy
Michele De Palma, Ioanna Keklikoglou
Tumor relapse after chemotherapy-induced regression is a major clinical problem, because it often involves inoperable metastatic disease. Tumor-associated macrophages (TAM) are known to limit the cytotoxic effects of chemotherapy in preclinical models of c ...
American Association for Cancer Research2015